Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 7/20 | 1.00 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28873241 | 0.88 | TARBP2 (0.79) | TARBP2PDCD4POLBGAAIKBKB | |
| SCHEMBL4918154 | 0.87 | TARBP2 (1.00) | TARBP2PDCD4POLBIKBKBKDM4E | |
| SCHEMBL28297242 | 0.87 | TARBP2 (1.00) | TARBP2PDCD4POLBGAAIKBKB | |
| SCHEMBL7907774 | 0.86 | TARBP2 (0.82) | TARBP2PDCD4POLBKDM4EALDH1A1 | |
| SCHEMBL17768259 | 0.86 | TARBP2 (0.82) | TARBP2PDCD4POLBKDM4EALDH1A1 | |
| SCHEMBL13771095 | 0.86 | TARBP2 (0.84) | TARBP2PDCD4POLBGAAIKBKB | |
| SCHEMBL18004097 | 0.86 | TARBP2 (0.75) | TARBP2PDCD4POLBKDM4EALDH1A1 | |
| SCHEMBL5192166 | 0.86 | TARBP2 (0.75) | TARBP2PDCD4POLBGAAIKBKB | |
| SCHEMBL3539144 | 0.86 | TARBP2 (0.84) | TARBP2PDCD4POLBGAAIKBKB | |
| SCHEMBL28295544 | 0.85 | TARBP2 (0.74) | TARBP2PDCD4POLBGAAIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106616029-B | Feed additive for improving disease resistance of rainbow trout and preparation method thereof | 西南大学 | 2020-05-01 | — | — | CN | claimed |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-109810071-B | miRNA biosynthesis inhibitor | 中国科学院成都生物研究所 | 2023-04-21 | — | — | CN | disclosed |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | disclosed |
| EP-3969439-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2022-03-23 | — | — | EP | disclosed |
| CN-114127049-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020230134-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020230134-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| CN-106578707-B | Immunity-improving feed for rainbow trout | 西南大学 | 2020-07-24 | — | — | CN | disclosed |
| EP-1430039-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | Aryx Therapeutics (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6680387-B2 | USING THIAZOLIDINONE COMPOUND | ARYX THERAPEUTICS | 2004-01-20 | — | — | US | disclosed |
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | disclosed |
| WO-2003024943-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ARYX THERAPEUTICS (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-02-06 | — | — | US | disclosed |
| US-5002960-A | Viricides for combating picornaviruses | STERLING DRUG, INC. (US) | 1991-03-26 | — | — | US | disclosed |
| US-4990595-A | Process for lowering the melt viscosity of aromatic polycarbonates, aromatic polyester carbonates and aromatic and/or araliphatic polyesters with super-critical gases | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-05 | — | — | US | disclosed |
| US-4939267-A | Viricides | STERLING DRUG INC. (US) | 1990-07-03 | — | — | US | disclosed |
| US-4843087-A | OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES | STERLING DRUG INC. (US) | 1989-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TARBP2 3124/4885PDCD4 4730/4885POLB 2775/4885 |
| US-20230084752-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | TARBP2 1563/4885PDCD4 903/4885POLB 1997/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TARBP2 3124/4885PDCD4 4730/4885POLB 2775/4885 |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ACSL3 | TARBP2 2276/4885PDCD4 2075/4885POLB 1877/4885 |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TARBP2 3124/4885PDCD4 4730/4885POLB 2775/4885 |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, ADSS2, GLS2 | TARBP2 1563/4885PDCD4 903/4885POLB 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.